Anthony Villano
Surgical Oncology · Philadelphia, PANPI 1710320635
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Merck at 56.9% of the total. Reporting peaked in 2023 at $2,781 and has fallen 67.9% since, to $891 in 2025.
Across 22 payments — averaging $199.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3K
- Intuitive Surgical$1K
- Boston Scientific$250
- Dilon Technologies, Inc.$191
- Johnson & Johnson$143
- Aadi Bioscience, Inc.$116
- plus $101 from 2 others
What the payments were for
- Consulting fees$2,50057%
- Travel & lodging$73417%
- Food & beverage$1,05924%
- Education$1042%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 2 | $2,500 |
| Intuitive Surgical | 10 | $1,094 |
| Boston Scientific | 2 | $250 |
| Dilon Technologies, Inc. | 2 | $191 |
| Johnson & Johnson | 3 | $143 |
| Aadi Bioscience, Inc. | 1 | $116 |
| Integra Lifesciences Corporation | 1 | $77 |
| Gilead | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$817
- HemoBlast Bellows$157
- AXIOS$117
- FYARRO$116
How this compares
$4,396 in reported general payments places this provider in the 75th percentile of 78 surgical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin Sulfate | 19 | $86 |
| Metronidazole | 18 | $15 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Philadelphia
- Richard BleicherPhiladelphia$53K
- Nestor EsnaolaPhiladelphia$17K
- Andrea PorpigliaPhiladelphia$11K
- Mark EtheringtonPhiladelphia$6K
- Stephanie GrecoPhiladelphia$3K
- James SunPhiladelphia$3K
- John RidgePhiladelphia$3K
- Steven StandifordPhiladelphia$487
- Alliric WillisPhiladelphia$254
- Jennifer ZhangPhiladelphia$200
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.